

Recurrences Seen After Excision in Early Rectal Ca

BY BETSY BATES

Los Angeles Bureau

SAN FRANCISCO — Treating early-stage rectal cancer with local resection alone has become increasingly common but poses a considerable long-term risk of local recurrence, even in patients with T1 tumors, according to the results of a large retrospective cohort study.

Dr. Y. Nancy You, of the Mayo Clinic in Rochester, Minn., reported follow-up data from the National Cancer Data Base on 765 patients who underwent local excision and 1,359 patients who underwent standard resection for stage I rectal cancer between 1994 and 1996. She presented the data at a symposium sponsored by the American Society of Clinical Oncology.

The 5-year local recurrence rates among



At 8 years post diagnosis, the local recurrence rate for resected T1 tumors had climbed to 14.3%.

DR. YOU

patients with complete resection (R0; no residual tumor) were substantially higher among patients who had local excision alone, compared with standard abdominal resection. For patients with T1 tumors, defined as those that invade only the submucosa, recurrence rates were 13% for local excision alone versus 7% for standard abdominal resection. For patients with T2 tumors, defined as those extending into the muscularis propria, recurrence rates were 22% versus 15%, respectively.

At 8 years post diagnosis, the local recurrence rate for completely resected T1 tumors had climbed to 14.3% among patients who underwent local excision alone, Dr. You said.

The type of surgery did not significantly affect overall 5-year survival rates for patients with T1 tumors, although patients with T2 tumors were more likely to survive if they underwent the more radical surgery rather than local excision (77% vs. 68%, respectively).

A multivariate analysis found that overall survival was independently associated with age at diagnosis, number of comorbidities, and number of postoperative complications for patients with T1 or T2 tumors.

Local excision alone spares most patients perioperative morbidity and preserves the sphincter, Dr. You said. Her review found that patients selected for local excision tended to have low-lying, small, low-grade tumors.

Lower rates of rehospitalization and perioperative complications were found in the patients who underwent local excision than in those who underwent complete resection for stage I disease.

Dr. You and associates concluded that appropriately selected patients with T1 tumors, including the elderly and patients with comorbid conditions that would increase surgical risk, can expect “acceptable

overall survival” from local excision. “However, they do face increased risk for a local recurrence in the long term, in exchange for a favorable perioperative course,” she said at the meeting.

Caution should be used in treating patients with T2 tumors with local resection alone, she advised. “I would reserve local excision alone only for those patients [with T2 tumors] whose medical risks are prohibitive,” Dr. You emphasized.

In an interview after the meeting, she

said the gold standard for patients with T2 tumors remains a standard abdominal resection, which she generally recommends to her patients when discussing the risks and benefits of either procedure.

“However, if the tumor characteristics are favorable for local excision and [the] patient is reluctant to undergo a large procedure, I would strongly consider a clinical trial,” she said.

Trials are underway to see whether chemoradiation in combination with local

excision lowers the risk of local recurrence in patients with stage I disease.

Dr. Heidi Nelson, chair of the colon and rectal surgery division at the Mayo Clinic, was a coinvestigator on the study. Researchers from the University of Minnesota and the American College of Surgeons also contributed. The meeting was co-sponsored by the American Gastroenterological Association, the American Society for Therapeutic Radiation and Oncology, and the Society of Surgical Oncology. ■

Give your patients the simplicity of **one**

One insulin. Two actions.
One simple way to help control diabetes.

NovoLog® Mix 70/30 is...

- **Simply dosed**—easy once- or twice-daily starter therapy^{1,2}
- **Effective**—once- and twice-daily dosing gets up to 70% of patients to ADA goal^{2*}
- **Safe**—low rate of hypoglycemia^{3,4}
- **Complete**—fasting (FPG) and postprandial (PPG) coverage^{1,5}
- **The patient-preferred pen**¹—NovoLog® Mix 70/30 FlexPen^{®6}
- **Covered**—on most managed care formularies

Satisfaction Guarantee[†] to help patients progress toward glycemic goals.

*ADA goal is A1C <7%.

[†]74% of patients preferred NovoLog® Mix 70/30 FlexPen® versus 9% who preferred insulin lispro mix 75/25 prefilled pen for overall ease of use. 17% of respondents had no preference.

[‡]Subject to program details included in the Satisfaction Guarantee Patient Folio.



NovoLog® Mix 70/30

70% insulin aspart protamine suspension and 30% insulin aspart injection, (rDNA origin)

Give your patients the simplicity of **one**

Important Safety Information: Because NovoLog Mix 70/30 has peak pharmacodynamic activity 1 hour after injection, it should be administered with meals. Any change of insulin should be made cautiously and only under medical supervision. Changes in insulin strength, manufacturer, type, species, or method of manufacture may result in the need for a change in dosage. NovoLog Mix 70/30 is contraindicated during episodes of hypoglycemia and in patients hypersensitive to NovoLog Mix 70/30 or one of its excipients. Because of differences in the action of NovoLog Mix 70/30 and other insulins, care should be taken in patients in whom these conditions may be clinically relevant (eg, patients who are fasting, have autonomic neuropathy, are using potassium-lowering drugs, or are taking drugs sensitive to serum potassium level). Do not mix NovoLog Mix 70/30 with any other insulin product.

The significance, with respect to the long-term clinical sequelae of diabetes, of the differences in postprandial hyperglycemia between treatment groups has not been established.

Indications and Usage: NovoLog Mix 70/30 is indicated for the treatment of patients with diabetes mellitus for the control of hyperglycemia.

Please see brief summary of Prescribing Information on adjacent page. FlexPen and NovoLog are registered trademarks of Novo Nordisk A/S. © 2006 Novo Nordisk Inc. 129960R March 2006